Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells

Targeted agents and immunotherapies: optimizing outcomes in melanoma

(2017) Jason J. Luke et al.   Nature Reviews Clinical Oncology

Drugging RAS: Know the enemy

(2017) Bjoern Papke et al.   SCIENCE

The ERK cascade inhibitors: Towards overcoming resistance

(2016) Galia Maik-Rachline et al.   DRUG RESISTANCE UPDATES

Phenotypic Characterization of a Comprehensive Set of MAPK1 /ERK2 Missense Mutants

(2016) Lisa Brenan et al.   Cell Reports

Genomic Classification of Cutaneous Melanoma

(2015) Rehan Akbani et al.   CELL

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts

(2015) K. Kemper et al.   EMBO Molecular Medicine

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas

(2015) Michael Krauthammer et al.   NATURE GENETICS

Recurrent inactivating RASA2 mutations in melanoma

(2015) Rand Arafeh et al.   NATURE GENETICS

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

The nuclear translocation of ERK1/2 as an anticancer target

(2015) Alexander Plotnikov et al.   Nature Communications

Dragging Ras Back in the Ring

(2014) Andrew G. Stephen et al.   CANCER CELL

ERKs in Cancer: Friends or Foes?

(2014) Xavier Deschênes-Simard et al.   CANCER RESEARCH

Tumour heterogeneity and the evolution of polyclonal drug resistance

(2014) Rebecca A. Burrell et al.   Molecular Oncology

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

(2014) Chong Sun et al.   NATURE

Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma

(2014) A Roesch   ONCOGENE

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors

(2013) E. J. Morris et al.   Cancer Discovery

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The RAF Inhibitor Paradox Revisited

(2012) Adrienne D. Cox et al.   CANCER CELL

Targeting NRAS in Melanoma

(2012) Fergal C. Kelleher et al.   CANCER JOURNAL

Activation of Ras/PI3K/ERK Pathway Induces c-Myc Stabilization to Upregulate Argininosuccinate Synthetase, Leading to Arginine Deiminase Resistance in Melanoma Cells

(2012) W.-B. Tsai et al.   CANCER RESEARCH

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

(2012) Kevin B. Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

(2012) Michael Krauthammer et al.   NATURE GENETICS

Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment

(2012) Margaret K. Callahan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

(2012) Fei Su et al.   NEW ENGLAND JOURNAL OF MEDICINE

MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas

(2011) Avaniyapuram Kannan Murugan et al.   CELL CYCLE

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

(2011) A. G. Gilmartin et al.   CLINICAL CANCER RESEARCH

Nuclear Extracellular Signal-Regulated Kinase 1 and 2 Translocation Is Mediated by Casein Kinase 2 and Accelerated by Autophosphorylation

(2011) A. Plotnikov et al.   MOLECULAR AND CELLULAR BIOLOGY

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Resistance to BRAF Inhibition in Melanomas

(2011) David B. Solit et al.   NEW ENGLAND JOURNAL OF MEDICINE

The MAPK cascades: Signaling components, nuclear roles and mechanisms of nuclear translocation

(2010) Alexander Plotnikov et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

(2010) Christophe Frémin et al.   Journal of Hematology & Oncology

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

RSK Is a Principal Effector of the RAS-ERK Pathway for Eliciting a Coordinate Promotile/Invasive Gene Program and Phenotype in Epithelial Cells

(2009) Ulrik Doehn et al.   MOLECULAR CELL

Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma

(2009) Lavanya H Palavalli et al.   NATURE GENETICS

Identification and Characterization of a General Nuclear Translocation Signal in Signaling Proteins

(2008) Dana Chuderland et al.   MOLECULAR CELL

Sensing and Integration of Erk and PI3K Signals by Myc

(2008) Tae Lee et al.   PLoS Computational Biology